Sub-Domain 7 · Specialty Clinical and Cross-Cutting Delivery

SD7 closes the D21 architecture at the convergence of six concurrent federal-policy-cycle mechanisms operating against PA-3 healthcare-delivery infrastructure through 2026-2027 — the IIJA reauthorization September 30, 2026 inflection point, the 340B Rebate Model Pilot post-vacatur trajectory under AHA v. Kennedy (D. Me., February 10, 2026), the Title X 2025-2026 administrative-disruption sequence (April 1, 2025 withholding through April 1, 2026 OPA $261M continuation grants with new guidelines), the Medicare telehealth extension through December 31, 2027 under Consolidated Appropriations Act 2026 (signed February 3, 2026), the OBBBA delivery-side flow-through (cross-reference SD2), and the MHPAEA 2024 Final Rule non-enforcement disposition (cross-reference SD6). The sub-domain integrates cross-domain principal-anchor content from D13 (IIJA inflection; Eastwick/Cobbs Creek cumulative-burden geography; PA-state-fiscal-architectural asymmetry) and D6 ([MC-03](https://github.com/square-party/square-party-site/blob/main/reference-info/verified-pa3-domain-content/D21-healthcare-delivery/D21_healthDeliv_verified_2026-05-11.md#mc-03) SDP AHERA DOJ DPA at school-environmental-health intersection; MC32 federal/state EJ-divergence affecting SAMHSA targeted-population funding). Substantive specialty service-line architecture at Penn Medicine, Temple Health, Jefferson Health, and CHOP plus Wills Eye and St. Christopher's; ESRD delivery under Medicare Part B; Veterans Health Administration architecture (cross-reference D24). MC57 / MC58 / MC59 candidate Both/And designations plus the Telehealth Both/And at [G21-SD7-04](https://github.com/square-party/square-party-site/blob/main/reference-info/verified-pa3-domain-content/D21-healthcare-delivery/D21_healthDeliv_verified_2026-05-11.md#g21-sd7-04) forward MC62 candidate carry the analytical territory.

Legal Architecture

Constitutional foundation

Specialty clinical and cross-cutting delivery operates under Article I § 8 (Commerce Clause; Spending Clause; General Welfare Clause; federal Medicare / Medicaid, 340B, Title X, Medicare Part B ESRD, IIJA, and Medicare telehealth architecture) and 10th Amendment (state regulatory authority for SUD, BH, hospital licensure, healthcare workforce licensure, and pharmacy regulation); 14th Amendment Equal Protection grounding for Title VI healthcare access analysis.

Federal statutory layer

IIJA (P.L. 117-58; Infrastructure Investment and Jobs Act / "Bipartisan Infrastructure Law"). Signed November 15, 2021; authorized $1.2 trillion total / $550 billion new investment FY 2022-FY 2026; expires September 30, 2026. Substantive transportation-program architecture deferred to D13 SD7 G13-SD7-01 PRINCIPAL ANCHOR. CRS R47573 (April 14, 2026) projects 5-year FY 2027 reauthorization gap $166 billion; 6-year gap $199 billion; HTF balance projected at ~$45 billion end of FY 2026 (~7 months avg outlays); CBO projects HTF depleted by 2028 with cumulative shortfall reaching $280 billion by 2034 per AGC. House T&I Committee has held over a dozen hearings since beginning of 2025 with Reps. David Rouzer (R-NC; T&I Subcommittee on Highways and Transit Chair) and Rick Larsen (D-WA; T&I Ranking Member) leading bipartisan effort. BASICS Act H.R. 7437 introduced February 9, 2026 by Reps. Bresnahan (R-PA) and McDonald Rivet (D-MI) is bipartisan bridge-repairs-and-safety-improvements legislation but not the master reauthorization vehicle.

Medicare Telehealth Statutory Architecture (Section 1834(m) of the Social Security Act). Authorizes Medicare telehealth payment architecture; CARES Act (P.L. 116-136) plus CAA 2021 plus CAA 2023 plus CAA 2024 plus continuing resolutions plus Consolidated Appropriations Act 2026 (signed February 3, 2026) extending Medicare telehealth flexibilities through December 31, 2027. CY 2026 Medicare Physician Fee Schedule Final Rule (October 31, 2025; CMS-1832-F) permanent: direct supervision via real-time two-way audio-visual telecommunications; virtual teaching physician presence; removal of telehealth frequency limits on subsequent inpatient and nursing facility visits; behavioral/mental health in-person visit requirement waived through December 31, 2027 (and grandfathered for beneficiaries who began services on or before January 30, 2026).

340B Drug Pricing Program (42 U.S.C. § 256b). Substantive architecture cross-reference SD5 G21-SD5-01 plus G21-SD5-02. SD7-specific surface: 340B at PA-3 anchor hospitals operating as DSH 340B-qualifying entities (Penn Medicine, Temple, Jefferson, CHOP — DSH eligibility requires owned/operated/contracted by state/local government plus disproportionate-share adjustment percentage of 11.75% or greater per CRS R48696). February 10, 2026 AHA v. Kennedy (D. Me., No. 25-cv-600) vacated and remanded to HHS the 340B Rebate Model Pilot Program Application Notice (August 1, 2025; 90 Fed. Reg. 36,163), Corrected Application Notice (August 7, 2025; 90 Fed. Reg. 38,165), and manufacturer-application approvals (October 30 - November 14, 2025). HRSA RFI on rebate models closed April 20, 2026. 2024 340B spending: $66.3 billion; DSH hospitals account for nearly $52 billion. HHS FY 2026 proposed budget would move 340B oversight from HRSA to CMS.

Title X (Public Health Service Act, 42 U.S.C. §§ 300 to 300a-6). Authorized 1970; HHS Office of Population Affairs (OPA) administration; 42 C.F.R. Part 59 regulations. FY 2025: $286.5 million enacted; FY 2026: $286 million enacted (signed by President despite Trump FY 2026 budget request to eliminate). 3,853 Title X clinics as of 2023 serving 2.8 million people. 2025-2026 Trump-administration administrative-disruption sequence: April 1, 2025 withholding of 16 grantees / 22 Title X grants / $65.8M / approximately 842,000 patients (~30% of Title X patient population) affected, including Pennsylvania as a partially-affected state; NFPRHA lawsuit filed April 24, 2025 in U.S. District Court, District of Columbia; December 2025 restoration of year-4 funds; March 13, 2026 HHS guidance with one-week response window (March 13-20) removing "Quality Family Planning" standards and equity/inclusion programmatic goals; April 1, 2026 OPA continuation grant total $261 million to 86 organizations (Phase 1 cited $286M; HHS announcement clarifies $261M actual continuation); April 3, 2026 Trump White House FY 2027 budget contains no Title X funding; April 3, 2026 new Title X grant guidelines posted requiring grantees to end DEI policies, protect parental rights in religious upbringing, enforce Hyde Amendment, and ensure funds do not benefit "illegal aliens"; 2019 "Protect Life Rule" formal reinstatement not yet completed via NPRM. Congressional response: March 16, 2026 Democratic Women's Caucus plus Reproductive Freedom Caucus letter signed by 128 Members to HHS Secretary Kennedy demanding one-year full funding extension. White House spokesperson statement "current Title X grants to Planned Parenthood will be the last" per Ms. Magazine — forward-trajectory signal not yet operative in formal grant architecture.

Medicare Part B ESRD coverage (42 U.S.C. § 1395rr). 100% coverage for ESRD beneficiaries regardless of age after qualifying period; PA-3 dialysis center delivery architecture operates under Medicare Part B fee-for-service or Medicare Advantage ESRD enrollment.

OBBBA Section 71401 Rural Health Transformation Fund (RHTF). $50 billion total / $10 billion annually 2026-2030; rural-only architecture; does not directly serve urban PA-3 healthcare-delivery infrastructure (cross-reference SD5 G21-SD5-01).

Veterans Choice / Community Care Network (CCN). 38 U.S.C. § 1703 architecture (MISSION Act of 2018; CCN 2.0). Substantive content cross-reference D24 SD1 plus SD4.

OSHA Bloodborne Pathogens Standard (29 C.F.R. § 1910.1030) plus Hazard Communication Standard (29 C.F.R. § 1910.1200) plus workplace violence guidance. Cross-reference D10 SD3.

AHERA / SDP DPA (cross-reference D6 MC-03 G6-SD4-02 PRINCIPAL ANCHOR). DOJ DPA filed June 26, 2025; 8 counts; 31 SDP buildings 2015-2023; 5-year judicial monitoring; first US school district criminally charged under AHERA; Penn $100M contribution to SDP environmental management; Frankford High closed. School-environmental-health intersection at PA-3 pediatric specialty (CHOP environmental health clinic; Penn Medicine pediatric environmental).

Title VI (42 U.S.C. § 2000d). Cross-reference D13 SD7 G13-SD7-02 / G13-SD2-07 Justice40 architecture revocation context per D6 G6-SD5-01.

One Big Beautiful Bill Act of 2025 (P.L. 119-21) cross-cutting provisions. Cross-reference SD2 G21-SD2-02 (Sections 71107/71109/71115/71117/71119); SD5 G21-SD5-04 (Section 71109 noncitizen Medicaid restrictions October 1, 2026); SD5 G21-SD5-07 (Section 71401 RHTF).

Federal agency layer

CMS. Administers Medicare Part B specialty service-line architecture; ESRD coverage; Medicare telehealth implementation per CY 2026 PFS Final Rule; Medicare Advantage telehealth coverage architecture.

HRSA Office of Pharmacy Affairs. Administers 340B Drug Pricing Program; pending HHS FY 2026 reorganization to move 340B to CMS.

HHS Office of Population Affairs (OPA). Administers Title X family planning architecture. HHS Secretary Robert F. Kennedy Jr. National Family Planning and Reproductive Health Association (NFPRHA) President Clare Coleman identified in advocacy-organization principal capacity per source-grounded NPR, Roll Call, KFF, and Health Law Policy Brief citations.

USDOT Federal Transit Administration (FTA) plus Federal Highway Administration (FHWA). USDOT Secretary Sean Duffy met with Congress July 2025 on reauthorization priorities; USDOT RFI deadline August 20, 2025. Cross-reference D13 SD7 PRINCIPAL ANCHOR for substantive IIJA architecture.

HHS Office for Civil Rights (OCR). Administers Title VI healthcare-access oversight.

U.S. Department of Veterans Affairs (VA) plus DOJ Office of Federal Contract Compliance Programs (OFCCP). Cross-reference D24 plus D10.

OSHA. Cross-reference D10 SD3.

ACGME. Cross-reference SD4 G21-SD4-02.

State statutory and agency layer

PA Health Care Facilities Act (35 P.S. § 448.101 et seq.). Cross-reference SD4 substantive content.

PA Public Welfare Code (62 P.S. § 101 et seq.). Cross-reference SD2 substantive content for PA Medicaid PPS architecture affecting specialty service-line reimbursement.

PA MCARE Act (40 P.S. § 1303.101 et seq.). Cross-reference SD4 G21-SD4-05 medical malpractice plus 2024 tort reform architecture.

PA Healthcare Workforce Licensure (multiple titles). PA Department of State Bureau of Professional and Occupational Affairs administers physician, nurse, PA, pharmacist licensure architecture.

PA Hospital and Healthsystem Association (HAP). Industry association representing PA hospitals; advocacy on OBBBA implementation, Medicare reimbursement, and 340B architecture.

Local statutory and agency layer

Philadelphia Code Title 6 (Health). Cross-reference SD2 plus SD4.

Philadelphia DPH (PDPH); DBHIDS; Philadelphia County Assistance Office (CAO). Cross-reference SD2-SD6.

School District of Philadelphia (SDP). Cross-reference D11 SD7 SDP-Penn partnership plus D6 MC-03 G6-SD4-02 SDP AHERA DOJ DPA PRINCIPAL ANCHOR.

PA-3 specialty clinical infrastructure. Penn Medicine specialty (Abramson Cancer Center; Penn Heart and Vascular Center; Penn neurology; Penn dialysis at HUP and Penn Presbyterian; specialty surgical); Temple Health specialty (Temple Lung Center; cardiology; specialty surgical); Jefferson Health specialty (Sidney Kimmel Cancer Center; Vickie and Jack Farber Institute for Neuroscience; specialty surgical; Methodist trauma center per SD4 Profile 4); CHOP pediatric specialty across all subspecialties plus 50+ Care Network locations; Wills Eye Hospital ophthalmology specialty; St. Christopher's Hospital for Children pediatric specialty (Tower Health-owned).

Cross-cutting structural features

Three structural features recur across the SD7 constituent profiles.

First, the six-mechanism convergence layer. PA-3 healthcare-delivery architecture in 2026-2027 operates at the intersection of IIJA reauthorization inflection, 340B post-vacatur uncertainty, Title X administrative-disruption sequence, Medicare telehealth post-2027 reversion risk, OBBBA flow-through, and MHPAEA non-enforcement. Each mechanism is independently legitimate at the federal-policy-cycle level; none intends the cumulative healthcare-delivery-architecture-fragility outcome that emerges from their concurrent operation.

Second, the legislative-deadline architecture. Five of the six mechanisms operate at discrete deadlines or rulemaking horizons through 2026-2027: IIJA expiration September 30, 2026; Medicare telehealth extension end December 31, 2027; 340B Rebate Pilot post-RFI rulemaking 2026-2027; OBBBA Section 71109 effective October 1, 2026; OBBBA Section 71107 6-month redetermination beginning December 2026. The pattern is unusual in the project's analytical territory: most delivery-side disruption emerges from slowly-shifting administrative variables; here it concentrates at discrete legislative-and-rulemaking moments.

Third, the cross-domain principal-anchor inheritance architecture. The deepest substantive analytical content on IIJA inflection, cumulative-burden geography, PA-state-fiscal asymmetry, and AHERA criminal-enforcement at SDP school-environmental-health intersection is owned by upstream domains (D13 plus D6) and inherited at SD7 as ESTABLISHED CONTEXT. SD7 cross-references with Standard 9 specificity; does not re-extend the substantive content.

Constituent profiles

These profiles illustrate the structural features above. Drawn from current statute, the verified February 10, 2026 AHA v. Kennedy vacatur, the verified Title X disruption sequence, the verified Medicare telehealth extension architecture, and documented PA-3 specialty-care institutional architecture; the people are composites.

Profile 1: Oncology patient at Penn Abramson navigating 340B pharmacy interface in West Philadelphia (MC58 candidate)

Constituent type: working-age PA-3 resident; new oncology diagnosis; commercial group health insurance (employer-sponsored); income approximately $58,000; West Philadelphia Core sub-area. Triggering event: diagnostic workup at primary care with referral to oncology specialty; treatment plan including chemotherapy and oncology-administered medications subject to 340B pricing architecture at DSH-qualifying anchor hospital.

Pathway through the institutional system. Constituent receives oncology consultation at Penn Abramson Cancer Center (cross-reference D2 SD4 substantive cancer architecture); treatment plan including chemotherapy infusion delivered at hospital outpatient setting; oncology-administered medications purchased by Penn Medicine at 340B-discounted price (typically 20-50% below standard wholesale acquisition cost); constituent's commercial insurance reimburses Penn Medicine at standard contracted rate; the spread between 340B price and standard reimbursement generates revenue used to cross-subsidize teaching, research, and uncompensated care at Penn Medicine. February 10, 2026 AHA v. Kennedy (D. Me.) vacated 340B Rebate Model Pilot Program Application Notice; HRSA RFI on potential rebate model closed April 20, 2026; HHS FY 2026 proposed budget would move 340B oversight from HRSA to CMS.

Outcome. Constituent receives oncology treatment at Penn Abramson; commercial insurance covers treatment at network rates; out-of-pocket exposure governed by plan deductible-and-coinsurance architecture. The MC58 candidate Both/And operates: substantive 340B upfront-discount architecture continues operative at PA-3 anchor hospitals AND structural HRSA post-RFI rulemaking plus potential HHS reorganization creates regulatory-architecture uncertainty for the oncology pharmacy revenue base.

Profile 2: ESRD patient navigating dialysis delivery under Medicare Part B in North Philadelphia

Constituent type: working-age PA-3 resident; ESRD diagnosis; qualifying for Medicare Part B coverage regardless of age after qualifying period; household income approximately $42,000; North/Northwest Core sub-area. Triggering event: end-stage renal disease requiring sustained dialysis; Medicare Part B 100% coverage architecture activates after qualifying period; selection of dialysis center within PA-3.

Pathway through the institutional system. Constituent receives ESRD diagnosis from primary care / specialty nephrology; coordinates transition to Medicare Part B coverage; selects dialysis center within PA-3 geographic accessibility; receives in-center hemodialysis typically 3 times per week or home peritoneal dialysis depending on clinical and home-situation factors; Medicare Part B covers 100% of qualifying ESRD services. PA-3 dialysis centers operate under CMS ESRD Conditions for Coverage (42 C.F.R. Part 494). Cross-reference SD1 Medicare architecture for dual-eligible coordination where applicable.

Outcome. Constituent receives sustained dialysis treatment under Medicare Part B coverage; geographic-access pattern depends on PA-3 dialysis center distribution. The ESRD coverage architecture is substantively stable; structural risk operates at OBBBA Medicaid delivery-side flow-through for the Medicaid-side Medicare-Medicaid dual-eligible architecture (cross-reference SD1 G21-SD1-04 plus SD2 G21-SD2-02).

Profile 3: Title X-served patient navigating PA partial-affected disruption sequence in South Philadelphia (MC59 candidate)

Constituent type: working-age PA-3 resident; low-income (approximately 185% FPL); uninsured or under-insured; reproductive-health-services need (contraception, STI screening, cancer screening); South/Southwest sub-area. Triggering event: sustained need for Title X-funded reproductive health services through the 2025-2026 administrative-disruption sequence.

Pathway through the institutional system. Constituent accesses PA-3-serving Title X clinic. Pennsylvania named among partially-affected states in April 1, 2025 administration withholding of 16 grantees / 22 grants / $65.8M / ~842,000 patients nationally. NFPRHA lawsuit April 24, 2025; December 2025 restoration of year-4 funds; March 13, 2026 HHS one-week guidance window removing "Quality Family Planning" standards and equity/inclusion programmatic goals; April 1, 2026 OPA continuation grants of $261M announced to 86 organizations including Planned Parenthood affiliates; April 3, 2026 new grant guidelines require grantees to end DEI policies, protect parental rights in religious upbringing, enforce Hyde Amendment, and ensure funds do not benefit "illegal aliens." Constituent receives contraception, STI testing/treatment, cancer screening, wellness checks at Title X clinic; clinic operational stability affected by administrative-disruption sequence.

Outcome. Constituent receives Title X-funded reproductive health services at PA-3-serving clinic; clinic operational continuity is the load-bearing variable. The MC59 candidate Both/And operates: substantive Title X $286M FY 2026 appropriation continues operative AND structural Trump-administration administrative-disruption sequence (April 2025 withholding plus March 2026 one-week guidance window plus April 3 2026 new guidelines plus potential 2019 Protect Life Rule reinstatement pending plus FY 2027 zero funding signal) creates operational instability at the clinic-services-delivery layer that affects sustained access. Cross-reference SD5 G21-SD5-02 for FQHC plus Title X interface.

Profile 4: Dual-eligible navigating Medicare-extended-through-2027 telehealth in Northwest Philadelphia (Telehealth Both/And)

Constituent type: PA-3 senior (age 70); dual-eligible Medicare plus Medicaid CHC; mobility-limiting chronic condition; sustained telehealth utilization for primary care, specialty cardiology follow-up, and behavioral-health treatment; Northwest sub-area. Triggering event: sustained telehealth utilization across primary care plus specialty plus behavioral health; Medicare telehealth flexibility extension architecture.

Pathway through the institutional system. Constituent accesses Medicare telehealth services under Section 1834(m) extended through December 31, 2027 under CAA 2026: home-based primary care telehealth without geographic restriction; audio-only cardiology follow-up where appropriate; behavioral-health telehealth without in-person visit requirement (grandfather provision applicable if services began on or before January 30, 2026); FQHC distant-site provider access via G2025 billing code through December 31, 2027. CY 2026 PFS Final Rule permanent provisions: direct supervision via audio-visual telecommunications; virtual teaching physician presence; permanent removal of telehealth frequency limits on subsequent inpatient/nursing facility visits. PA Act 98 of 2022 permits audio-only telehealth for PA-state Medicaid coverage in outpatient psychiatric and SUD clinics (cross-reference SD6).

Outcome. Constituent receives sustained telehealth-mediated care across primary, specialty, and behavioral health domains through December 31, 2027. The Telehealth Both/And at G21-SD7-04 (forward MC62 candidate) operates: substantive telehealth-access architecture continues operative through 2027 (with select permanent provisions for behavioral-health audio-only and direct supervision) AND structural reversion-to-pre-PHE-architecture risk operates after December 31, 2027 absent further Congressional action — the December 31, 2025 EPTC expiration precedent (cross-reference SD3 G21-SD3-01) demonstrates legislative-deadline-driven disruption pattern that informs forward planning.

Conversational note

The most analytically important feature visible at SD7 is the convergence. The PA-3 healthcare-delivery architecture in 2026-2027 operates at the intersection of six concurrent federal-policy-cycle mechanisms that each have their own intended effect and none of which intends the cumulative outcome on healthcare-delivery-infrastructure-fragility at the PA-3 level. The IIJA reauthorization September 30, 2026 inflection point operates as a discrete legislative deadline affecting transportation-and-infrastructure architecture with healthcare-delivery-adjacent flow-through; D13 SD7 G13-SD7-01 PRINCIPAL ANCHOR documents that as of May 2026 no reauthorization bill has been introduced and that the Highway Trust Fund balance is projected at ~$45 billion (seven months of average outlays) at end of FY 2026. The Medicare telehealth flexibility extension through December 31, 2027 under Consolidated Appropriations Act 2026 (signed February 3, 2026) sustains delivery architecture for ~22 months but creates another discrete legislative deadline at 12/31/27. The 340B Rebate Model Pilot post-court-vacatur (AHA v. Kennedy, D. Me., February 10, 2026) plus HRSA RFI closed April 20, 2026 plus HHS FY 2026 proposed budget move of 340B oversight from HRSA to CMS operates as an administrative-architecture-uncertainty mechanism affecting PA-3 anchor hospital pharmacy revenue base. The Title X 2025-2026 administrative-disruption sequence (April 2025 withholding → December 2025 restoration → March 13, 2026 one-week guidance window → April 1, 2026 OPA $261M continuation grants → April 3, 2026 new guidelines plus FY 2027 zero funding signal) operates as a sustained administrative-pressure mechanism on PA-3-serving Title X clinics. The OBBBA Medicaid delivery-side flow-through (cross-reference SD2 G21-SD2-02; SD5 G21-SD5-01) operates across multiple architectural layers affecting BH-MCO capitation, provider-tax safe-harbor stepdown, 6-month redetermination procedural-loss, and noncitizen Medicaid restrictions. The MHPAEA 2024 Final Rule Trump-administration partial non-enforcement disposition (cross-reference SD6 G21-SD6-02) operates at the federal-floor parity layer. Each mechanism is independently legitimate at the federal-policy-cycle level; none intends the cumulative healthcare-delivery-architecture-fragility outcome that emerges from their concurrent operation.

The most common misunderstanding about specialty and cross-cutting healthcare delivery in 2026 is that the post-PHE telehealth-flexibility architecture is now stable. It is not. The post-COVID-PHE telehealth architecture has operated under repeated short-term extensions — September 30, 2025 expiration; restored via November 12, 2025 continuing resolution through January 30, 2026; further extended via CAA 2026 (signed February 3, 2026) through December 31, 2027. Three permanent provisions stand on solid statutory ground: behavioral / mental health audio-only telehealth (permanent under certain conditions); direct supervision via real-time audio-visual telecommunications (CY 2026 PFS Final Rule); virtual teaching physician presence (CY 2026 PFS Final Rule). The remainder operates under the December 31, 2027 sunset. Stakeholders are increasingly pushing for stand-alone permanent telehealth legislation to reduce the disruption caused by reliance on short-term funding bills. The Telehealth Both/And operationalizes: substantive telehealth access continues operative through 2027 AND structural reversion-to-pre-PHE-architecture risk operates after 12/31/27.

The human consequence visible in 2026 concentrates at three convergence layers. First, PA-3 anchor hospital specialty service delivery (oncology at Penn Abramson; cardiology at Penn Heart and Vascular; pediatric specialty at CHOP; neurology at Jefferson Vickie and Jack Farber Institute) operates with a 340B pharmacy revenue cross-subsidy supporting teaching, research, and uncompensated care under the structural regulatory uncertainty of the post-court-vacatur HRSA RFI rulemaking trajectory plus potential HHS reorganization moving 340B oversight to CMS. Second, PA-3 Title X-served patients experience administrative-disruption-sequence operational instability while the $286M FY 2026 appropriation continues operative at the statutory level; the March 13, 2026 HHS one-week guidance window removing "Quality Family Planning" standards plus the April 3, 2026 new grant guidelines represent a substantive shift in program design even as funding flows. Third, PA-3 healthcare-delivery-adjacent infrastructure (SEPTA transit to academic medical centers; FHWA road infrastructure affecting EMS routing) faces the September 30, 2026 IIJA expiration inflection point absent reauthorization or extension; the cross-domain principal-anchor cumulative-burden geography concentration in Eastwick / Cobbs Creek (D13 G13-SD4-05; G13-SD6-05) plus North/Northwest Core plus West Philadelphia Core sub-areas compounds healthcare-access disparities with the upstream environmental-burden architecture (cross-reference D13 plus D6 PRINCIPAL ANCHORS).

The most analytically important federal-engagement feature visible at SD7 is the legislative-deadline architecture. Five of the six concurrent federal-policy-cycle mechanisms above operate at discrete deadlines or rulemaking horizons through 2026-2027: IIJA expiration September 30, 2026; Medicare telehealth extension end December 31, 2027; 340B Rebate Pilot post-RFI rulemaking 2026-2027; OBBBA Section 71109 effective October 1, 2026; OBBBA Section 71107 6-month redetermination beginning December 2026. Federal House representation operates at each deadline directly through legislation, appropriation, and oversight authority; the legislative-deadline architecture means single-mechanism engagement may address one mechanism without addressing the cumulative architecture per the MC55 SD5 emergent-from-interaction HOM 2nd-instance shape diagnostic. PA-state-level texture engagement at PA Medicaid PPS rate-setting (PA DHS), PA OMHSAS Behavioral HealthChoices contracting, PA Insurance Department MHPAEA enforcement, PA Hospital and Healthsystem Association advocacy, and PA Department of Health hospital licensure operates at the complementary state-level locus.

Geography & representation

Data provenance. IIJA P.L. 117-58 September 30, 2026 expiration, CRS R47573 (April 14, 2026) plus CRS R48644 HTF projections, House T&I Committee leadership (Rouzer R-NC; Larsen D-WA), and BASICS Act H.R. 7437 (Bresnahan R-PA / McDonald Rivet D-MI February 9, 2026) are documented in CRS publications, House committee records, and Funding Landscape / T4America tracking. Medicare telehealth statutory architecture (Section 1834(m)), CAA 2026 (signed February 3, 2026) extension through December 31, 2027, CY 2026 Medicare Physician Fee Schedule Final Rule (October 31, 2025; CMS-1832-F), and CMS Telehealth FAQ (2/26/26) are documented in CMS Federal Register and CMS guidance. AHA v. Kennedy, No. 25-cv-600 (D. Me., February 10, 2026) vacatur and HRSA RFI 91 Fed. Reg. 7,287 (February 17, 2026; closed April 20, 2026) are documented in D. Me. court records and HHS Federal Register. Title X 2025-2026 administrative-disruption sequence (April 1 2025 withholding $65.8M / 16 grantees / 22 grants / 842,000 patients; NFPRHA lawsuit April 24, 2025; December 2025 restoration; March 13, 2026 HHS one-week guidance window; April 1, 2026 OPA $261M continuation grants to 86 organizations; April 3, 2026 new guidelines plus FY 2027 zero funding) is documented in Guttmacher, KFF, CRS IF10051, NPR, Roll Call, Health Law Policy Brief, and Ms. Magazine sources. The March 16, 2026 128-Member letter (DWC Whip Williams GA-05; RFC Vice Chair Fletcher TX-07; Chu CA-28; Davids KS-03; Titus NV-01 lead) is documented in House delegation records. 340B Drug Pricing Program 2024 spending $66.3 billion with DSH at ~$52 billion is documented in 340B program reporting and Wikipedia / Medicine to Market sources. PA-3 dialysis center roster, PA-3 anchor hospital 340B pharmacy revenue magnitude, PA-3 Title X clinic roster, PA-3 telehealth utilization magnitude, PA-3 oncology specialty volume, PA-3 nursing workforce capacity, and PA-3 pharmacist workforce capacity are flagged for institutional retrieval.

PA-3 statistical profile. PA-3 specialty institutional roster includes Penn Medicine (HUP at 3400 Spruce Street; Penn Presbyterian Medical Center at 51 N. 39th Street; Pennsylvania Hospital at 800 Spruce Street; Abramson Cancer Center; Penn Heart and Vascular Center), Temple Health (Temple University Hospital at 3401 N. Broad Street; Episcopal Campus at 100 E. Lehigh Avenue; Temple Lung Center), Jefferson Health (Thomas Jefferson University Hospitals at 111 S. 11th Street; Einstein Medical Center at 5501 Old York Road; Jefferson Methodist at 2301 S. Broad Street; Sidney Kimmel Cancer Center; Vickie and Jack Farber Institute for Neuroscience), CHOP (3401 Civic Center Boulevard plus 50+ Care Network locations), Wills Eye Hospital (840 Walnut Street), and St. Christopher's Hospital for Children (1601 W. Allegheny Avenue). 340B 2024 spending $66.3 billion with DSH at nearly $52 billion; Penn Medicine, Temple, Jefferson, CHOP all qualify as DSH 340B entities. Title X FY 2025 $286.5M and FY 2026 $286M enacted; April 1, 2026 OPA $261M continuation grants to 86 organizations; 3,853 Title X clinics nationally serving 2.8 million patients. Medicare telehealth extension through December 31, 2027 under CAA 2026. IIJA expires September 30, 2026; CRS R47573 projects $166B 5-year and $199B 6-year reauthorization gaps; HTF balance ~$45 billion at end FY 2026.

Geographic variation.

• North/Northwest Philadelphia Core. Temple University Hospital and Episcopal Campus serve as primary specialty anchor capacity. Cumulative-disadvantage-geography concentration intersects with specialty-care access architecture; PA-3 dialysis center distribution interacts with documented chronic-disease prevalence.
• West Philadelphia Core. Penn Medicine (HUP, Penn Presbyterian, Pennsylvania Hospital, Abramson, Penn Heart and Vascular), CHOP, Jefferson Center City. Highest density of specialty-care capacity in PA-3. 340B pharmacy revenue cross-subsidy concentrates here.
• Northwest Philadelphia. Einstein Medical Center (Jefferson Einstein post-2021); CHOP Care Network locations distributed across pediatric specialty.
• South/Southwest Philadelphia. Jefferson Methodist (with EMTALA-protected transfer pathway to Jefferson Center City for higher-acuity per SD4); Eastwick / Cobbs Creek cumulative-burden geography concentration per D13 G13-SD4-05 plus G13-SD6-05 PRINCIPAL ANCHORS compounds healthcare-access disparities.

PA-3 sub-area-disaggregated dialysis center distribution, Title X clinic roster, telehealth utilization, and specialty-care utilization are not retrievable from public-facing data products and are flagged for institutional retrieval.

Gap analysis

Six structural gaps recur across the constituent profiles and the architectural layers above.

G21-SD7-01 — IIJA reauthorization September 30, 2026 inflection-point delivery-side flow-through (MC57 candidate Both/And; D13 G13-SD7-01 PRINCIPAL ANCHOR cross-reference). Substantive infrastructure continuity: IIJA signed November 15, 2021 authorized $1.2 trillion total / $550B new investment FY 2022-FY 2026 supporting SEPTA transit to PA-3 academic medical centers, FHWA road infrastructure affecting EMS routing and patient access. Structural reauthorization inflection-point risk: IIJA expires September 30, 2026; as of May 2026, no reauthorization bill introduced. CRS R47573 projects 5-year FY 2027 reauthorization gap $166B; 6-year gap $199B; HTF balance projected at ~$45B end FY 2026; CBO projects FTA may delay payments Q3 FY 2027, FHWA Q2 FY 2028. House T&I Committee has held over a dozen hearings since beginning of 2025 with Reps. Rouzer (R-NC) and Larsen (D-WA) leading bipartisan effort; September 2025 announcement of intent for "bipartisan, multi-year surface transportation reauthorization." BASICS Act H.R. 7437 introduced February 9, 2026 by Bresnahan (R-PA) and McDonald Rivet (D-MI) is legislative activity but not master vehicle. Trump Administration FY 2027 budget preparing for reauthorization not maintaining IIJA funding levels. Representation implication: Federal House representation has direct legislative authority; PA House delegation engagement (Bresnahan R-PA among bipartisan BASICS Act introducers) operative at legislative-text-development layer.

G21-SD7-02 — 340B Drug Pricing Program Rebate Model Pilot court vacatur plus HRSA RFI post-April-20-2026 rulemaking trajectory at PA-3 anchor hospital pharmacy revenue architecture (MC58 candidate Both/And; cross-reference SD5 G21-SD5-01 plus G21-SD5-02). Substantive 340B continuity: Penn Medicine, Temple Health, Jefferson Health, CHOP all qualify as DSH 340B entities. 2024 340B spending: $66.3 billion (record); DSH hospitals account for nearly $52 billion. 340B discount magnitude typically 20-50% below standard WAC; revenue used to cross-subsidize teaching, research, and uncompensated care. Structural post-court-vacatur uncertainty: February 10, 2026 AHA v. Kennedy (D. Me., No. 25-cv-600) vacated and remanded to HHS the 340B Rebate Model Pilot Program Application Notice plus Corrected Application Notice plus manufacturer-application approvals. HRSA RFI on potential rebate model use closed April 20, 2026. HHS FY 2026 proposed budget would move 340B oversight from HRSA to CMS. Representation implication: Federal House representation has direct legislative authority on 340B statutory amendments (cross-reference SD5 H.R. 7391 bipartisan); oversight authority on HRSA plus CMS rulemaking trajectory.

G21-SD7-03 — Title X family planning Trump-administration 2025-2026 administrative-disruption sequence plus Pennsylvania partial-affected exposure (MC59 candidate Both/And). Substantive Title X appropriation continuity: FY 2025 plus FY 2026 appropriation $286.5M plus $286M enacted; Congress included Title X in 2026 appropriation despite Trump FY 2026 budget request to eliminate. 3,853 Title X clinics serving 2.8 million patients. April 1, 2026 OPA continuation grants of $261M to 86 organizations including Planned Parenthood affiliates. Structural administrative-disruption sequence: April 1, 2025 administration withholding of 16 grantees / 22 Title X grants / ~$65.8M / ~842,000 patients affected (~30% of Title X patient population); Pennsylvania named among partially-affected states; NFPRHA lawsuit filed April 24, 2025; December 2025 HHS restoration of year-4 funds; March 13, 2026 HHS one-week guidance window removing "Quality Family Planning" standards and equity/inclusion programmatic goals; April 3, 2026 Trump White House FY 2027 budget contains no Title X funding plus new Title X grant guidelines requiring grantees to end DEI policies, protect parental rights in religious upbringing, enforce Hyde Amendment, and ensure funds do not benefit "illegal aliens." Pending: potential reinstatement of 2019 "Protect Life Rule." Congressional response: March 16, 2026 128-Member letter to HHS Secretary Kennedy demanding one-year full funding extension. Representation implication: Federal House representation has direct legislative authority on Title X appropriation and statutory architecture; oversight authority on HHS OPA implementation.

G21-SD7-04 — Medicare telehealth post-December 31, 2027 reversion risk plus select permanent provisions (Telehealth Both/And; forward MC62 candidate). Substantive telehealth extension through 12/31/27: Medicare telehealth flexibilities extended through December 31, 2027 under Consolidated Appropriations Act 2026 signed February 3, 2026: home-based telehealth without geographic restriction; audio-only non-behavioral telehealth; FQHCs and RHCs as distant-site providers via G2025; expanded distant-site practitioner list; behavioral / mental telehealth without in-person visit requirement (grandfather provision for beneficiaries who began services on or before January 30, 2026). CY 2026 PFS Final Rule permanent provisions: direct supervision via audio-visual telecommunications; virtual teaching physician presence; permanent removal of telehealth frequency limits on subsequent inpatient / nursing facility visits; behavioral / mental health audio-only telehealth permanent under certain conditions. Structural December 31, 2027 reversion risk: Absent further Congressional action, Medicare telehealth flexibilities revert to pre-PHE architecture on December 31, 2027. Repeated short-term extension pattern (September 30, 2025 expiration → November 12, 2025 CR through January 30, 2026 → CAA 2026 through December 31, 2027) creates planning-horizon disruption. Representation implication: Federal House representation has direct legislative authority on Medicare telehealth statutory architecture; stand-alone permanent telehealth legislation operates as primary federal-engagement variable.

G21-SD7-05 — PA-3 specialty network adequacy plus cross-cutting workforce architecture. PA-3 specialty service-line concentration at Penn Medicine, Temple, Jefferson, CHOP operates alongside documented primary-care workforce gap downstream of specialty-selection economics under ACGME-accredited GME architecture (cross-reference SD4 G21-SD4-02). Specialty-network adequacy at PA Medicaid PH-MCO / CHC-MCO / commercial MA architecture (SD2 G21-SD2-05). MAT Act plus DEA-HHS permanent telemedicine flexibility for buprenorphine prescribing has addressed principal SUD workforce-access bottleneck (SD6 G21-SD6-03). Representation implication: Federal Medicare GME architecture under direct federal House authority; specialty-distribution-incentive design as policy territory.

G21-SD7-06 — Cross-domain principal-anchor integration: D13 cumulative-burden geography plus D13 IIJA inflection plus D13 PA-state-fiscal asymmetry plus D6 MC-03 AHERA G6-SD4-02 plus D6 MC32 EJ-divergence at PA-3 healthcare-delivery architecture interface. PA-3 healthcare-delivery architecture is structurally shaped by cross-domain principal-anchor content owned by upstream domains: D13 G13-SD7-01 IIJA reauthorization inflection point; D13 G13-SD4-05 plus G13-SD6-05 plus G13-SD2-07 cumulative-burden geography (Eastwick / Cobbs Creek South/Southwest concentration plus North/Northwest Core plus West Philadelphia Core equity-gap sub-areas); D13 PA-state-fiscal-architectural asymmetry; D6 MC-03 G6-SD4-02 SDP AHERA DOJ DPA (school-environmental-health intersection at PA-3 pediatric specialty CHOP environmental health clinic and Penn pediatric environmental); D6 MC32 federal/state EJ-divergence (affecting SAMHSA targeted-population funding, harm-reduction architecture, and culturally-responsive treatment funding per SD6 cross-reference). SD7 cross-references with Standard 9 specificity; does NOT re-extend substantive content. Representation implication: Cross-reference D13 plus D6 verified-file representation implications.

Where this leads

Federal House representation operates at five concurrent legislative-deadline trajectories at SD7: IIJA reauthorization through September 30, 2026; Medicare telehealth permanent legislation through December 31, 2027; 340B Rebate Pilot post-RFI rulemaking (and H.R. 7391 Senate progression per SD5); Title X appropriation through FY 2027 cycle plus 2019 Protect Life Rule reinstatement NPRM; OBBBA technical-corrections legislation affecting Sections 71107 / 71109 / 71115 / 71117 / 71119 (cross-reference SD2). PA-state-level texture engagement at PA Medicaid PPS rate-setting, PA OMHSAS Behavioral HealthChoices contracting, PA Insurance Department MHPAEA enforcement, PA Hospital and Healthsystem Association advocacy, and PA Department of Health hospital licensure is the principal complementary locus.

The MC57 / MC58 / MC59 candidate Both/And designations plus the Telehealth Both/And at G21-SD7-04 forward MC62 candidate captures the central analytical posture at SD7: substantive federal architecture across IIJA, 340B, Title X, and Medicare telehealth continues operative AND structural inflection-point / administrative-disruption / rulemaking-trajectory mechanisms operate at meaningful magnitude through 2026-2027. The convergence layer documents six concurrent federal-policy-cycle mechanisms; the cross-domain principal-anchor inheritance from D13 (IIJA plus cumulative-burden plus PA-fiscal asymmetry) and D6 (MC-03 AHERA plus MC32 EJ-divergence) closes the D21 architecture at the cross-cutting layer.

SD7 closes Phase 1 of the D21 architecture. The synthesis pages that follow — Neighbors, Recent Changes, The Gaps, and Legal Text — integrate the seven sub-domain analyses at the domain level.